MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acn3.70078

Медицинская библиотека · Annals of clinical and translational neurology · 2025

Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases.

Segarra-Casas Alba, Domínguez-González Cristina, Natera-de Benito Daniel, Kapetanovic Solange, Hernández-Laín Aurelio, Estévez-Arias Berta, Llansó Laura, Ortez Carlos, Jou Cristina, Martí-Carrera Itxaso, López-Márquez Arístides, Rodríguez Maria José, González-Mera Laura, Nedkova Velina, Fernández-Torrón Roberto, Rodríguez-Santiago Benjamín, Jimenez-Mallebrera Cecília, Juntas-Morales Raul, López-de Munain Adolfo, Surrallés Jordi, Nascimento Andrés, Gallardo Eduard, Olivé Montse, Gallano Pia, González-Quereda Lidia

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Approximately half of patients with hereditary myopathies remain without a definitive genetic diagnosis after DNA next-generation sequencing (NGS). Here, we implemented transcriptome analysis of muscle biopsies as a complementary diagnostic tool for patients with muscle disease but no definitive genetic diagnosis after exome sequencing.

METHODS

In total, 70 undiagnosed cases with suspected genetic muscular dystrophies or congenital myopathies were included in the study. Muscle RNAseq comprised the analysis of aberrant splicing, aberrant expression, and monoallelic expression. In addition, existing NGS data or variant calling from RNAseq were reanalyzed, and genome sequencing was performed in selected cases. Four aberrant splicing open-source tools were compared and assessed.

RESULTS

RNAseq established a diagnosis in 10/70 patients (14.3%) by identifying aberrant transcripts produced by single nucleotide variants (7/10) or copy number variants (3/10). Reanalysis of NGS data allowed the diagnosis in 9/70 individuals (12.9%). Based on this cohort, FRASER was the tool that reported more splicing outlier events per sample while showing the highest accuracy (81.26%).

CONCLUSIONS

We demonstrate the utility of RNAseq in identifying causative variants in muscle diseases. Evaluation of four aberrant splicing tools allowed efficient identification of most pathogenic splicing events, obtaining a manageable number of candidate events for manual inspection, demonstrating feasibility for translation into a clinical setting. We also show how the integration of omic technologies reduces the turnaround time to identify causative variants.

Для цитирования: Segarra-Casas Alba, Domínguez-González Cristina, Natera-de Benito Daniel, Kapetanovic Solange, Hernández-Laín Aurelio, Estévez-Arias Berta, Llansó Laura, Ortez Carlos, Jou Cristina, Martí-Carrera Itxaso, López-Márquez Arístides, Rodríguez Maria José, González-Mera Laura, Nedkova Velina, Fernández-Torrón Roberto, Rodríguez-Santiago Benjamín, Jimenez-Mallebrera Cecília, Juntas-Morales Raul, López-de Munain Adolfo, Surrallés Jordi, Nascimento Andrés, Gallardo Eduard, Olivé Montse, Gallano Pia, González-Quereda Lidia. Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases.. Annals of clinical and translational neurology. 2025. DOI: 10.1002/acn3.70078.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.